Centessa Pharmaceuticals plc American Depositary Shares (CNTA)
Company News
Nxera Pharma reported progress in its obesity and metabolic disease pipeline, achieved R&D milestones with AbbVie, and advanced cancer immunotherapy trials. The company experienced increased R&D expenses and a wider operating loss compared to the previous period.
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. Take-Two reported third-quarter total net bookings of $1.34 billion, down 3% year-over-year. The company also revised its 2024 net bookings forecast to $5.25 billion and $5.3 billion, down from $5.45 billion and $...